Items Tagged ‘withdrawn’

April 27, 2016

Pacritinib Development in Myelofibrosis Placed on Clinical Hold by the FDA


The investigative agent, pacritinib, being evaluated for treatment of myelofibrosis has been placed on full clinical hold by the United States Food and Drug Administration (FDA). All trials including treatment involving pacritinib have been stopped, and the New Drug Application (NDA) to the FDA for pacritinib has been withdrawn.1 Myelofibrosis is a type of blood […]

View full entry

Tags: clinical hold, fda, mpn, myelofibrosis, myeloproliferative neoplasm, Myeloproliferative Neoplasms MPN, NDA, News, pacritinib, withdrawn